**Supplemental figures legend**

**Figure S1.** Xenograft tumour volume assessment for the efficacy experiment. Tumour volume is displayed as percentage and normalized for baseline values and presented for UZLX-GIST3 (A), UZLX-GIST4 (B), UZLX-GIST2 (C), and GIST48 (D).

**Figure S2.** The assessment of the effect of PI3K inhibitors and their combination with IMA on KIT signalling in UZLX-GIST3 (A), UZLX-GIST4 (B), UZLX-GIST2 (C) and GIST48 (D) tumours. Tumours specimens were snap-frozen at week two, upon treatment discontinuation.